PROTAC EED degrader-1 is primarily utilized in the field of targeted protein degradation, a cutting-edge approach in drug discovery and therapeutic development. It functions by selectively degrading the EED protein, a component of the Polycomb Repressive Complex 2 (PRC2), which plays a critical role in gene silencing and epigenetic regulation. By degrading EED, this compound helps in studying the biological functions of PRC2 and its involvement in diseases such as cancer, where PRC2 is often dysregulated. It serves as a valuable tool for researchers to explore potential therapeutic strategies aimed at modulating epigenetic mechanisms, offering insights into novel treatments for cancers and other diseases linked to epigenetic abnormalities. Additionally, it aids in understanding the broader implications of protein degradation technology in drug development.